While simple steatosis may be clinically stable, nonalcoholic steatohepatitis (NASH) can be progressive. Inflammation is believed to be the driving force behind NASH and the progression to ...

Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

NASH is a complex liver disease marked by too much fat buildup in liver cells and inflammation. To create precise treatments, it is crucial to fully grasp how NASH-related biomarkers work in both ...

1). That suggests HepaStem could act on the mechanisms of cirrhosis, fibrosis, and control the acute and sub chronic inflammation that respectively contributes to ACLF and NASH. These are major ...

In the phase 2b trial lanifibranor met twin endpoints relating to inflammation resolution and ... doses producing significant improvements in NASH resolution without worsening of fibrosis ...

One such disease, nonalcoholic steatohepatitis (NASH), is characterized by dysregulated metabolism, inflammation and fibrosis. According to Axcella’s Chief Medical Officer and Executive Vice ...

Roche’s Genentech unit bought Jecure Therapeutics and its portfolio of NLRP3 drugs in 2018, focusing on peripheral drugs for NASH, liver fibrosis, gout, inflammatory bowel disease, and ...

The presence of inflammation on liver biopsy is associated with the development of advanced fibrosis in NASH. The presence of acinar inflammation is essential for the histological diagnosis of ...